$164.00
+2.12 (+1.31%)
CRAI News15 articles
Massachusetts City Moves to Ban Crypto ATMs Amid Fraud Crackdown
Haverhill, Massachusetts is advancing a ban on cryptocurrency ATMs, requiring removal within 60 days or daily fines. The move follows a unanimous council vote and growing fraud concerns.
European Gas Volatility Continues as Qatar LNG Outage Sparks Supply Scramble
European natural gas prices whipsawed, settling lower despite a persistent supply shock from Qatar. Italy is securing alternative supplies as Cheniere Energy reports operating at maximum capacity.
Fundrise VCX Soars on NYSE, Defying Market Downturn as AI Craze Fuels Demand
Fundrise's VCX, a public venture capital fund, closed at $117.70, up 54.5% since its NYSE debut, trading at a steep premium to net asset value. The fund's heavy allocation to private AI companies drove demand despite broader market declines.
U.S. LNG Stocks Rally as Qatar Supply Shock Sparks Global Scramble
Shares of U.S. liquefied natural gas exporters rallied sharply after an attack on Qatar's export facilities removed a significant portion of global supply, prompting nations like Italy and Japan to urgently seek alternative sources.
VIX Plunges from 14-Month High as Bitcoin Tops $70K, Oil Crashes 11%
The Cboe Volatility Index fell to 24.93 after hitting 35.3 Monday. Bitcoin climbed above $70,000 as oil prices tumbled, leaving major U.S. stock indexes mixed.
Zealand Pharma Stock Crashes on Obesity Drug Data Lagging Lilly
Zealand Pharma A/S shares plunged over 32% Friday after mid-stage trial results for its obesity drug candidate petrelintide showed weight loss well behind Eli Lilly's competing therapy, erasing billions in market value.
Aristocrat Leisure Shares Slide on Interactive Growth Concerns
Aristocrat Leisure shares declined sharply following its annual meeting, where management noted interactive content revenue is lagging behind targets. The stock closed near a 52-week low.
Aristocrat Leisure shares slip on AI investment, white-label exit plan
Aristocrat Leisure shares declined 0.65% on Thursday as the company outlined plans to exit its white-label online unit and boost artificial intelligence spending during its annual general meeting.
Aristocrat Leisure Shares Hold Steady Ahead of Annual Meeting
Aristocrat Leisure shares edged up 0.04% to A$49.53 in Sydney trading, with investors awaiting management commentary at Thursday's annual meeting following recent volatility.
Crypto Kiosk Fraud Prompts Regulatory Crackdown Across U.S. States
Americans lost over $333 million to cryptocurrency ATM scams in 2025, driving lawmakers in at least 15 states to propose stricter rules including registration mandates and enhanced warnings.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Moutai App Maintenance and Order Crackdown Draw Investor Scrutiny Ahead of Trading
Kweichow Moutai's iMoutai app undergoes overnight maintenance and refunds flagged orders, putting focus on its direct-sales channel as shares prepare for Monday trading.
Hims Halts Compounded GLP-1 Pill as FDA Cracks Down, Molina Plunges on Profit Warning
Hims & Hers discontinues its $49 compounded semaglutide offering following FDA enforcement signals, sending shares down 16%. Molina Healthcare forecasts 2026 profit far below expectations, triggering a 28% stock drop.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.